XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Cash flows from operating activities:      
Net loss $ (54,402,131) $ (33,135,404)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 660,697 809,559  
Amortization of intangible assets 136,770 136,770  
Change in fair value of derivative liability 0 13,221,977  
Stock-based compensation 9,595,947 4,001,553  
Non-cash interest expense (31,281) 213,559  
Loss on short-term investments 10,151 475,490  
Settlement of receivable with shares of common stock from affiliated entity (PLS) 0 (1,713,770)  
(Gain) loss on equity investment in affiliated entities 830,475 (13,181,619)  
Share of net loss in Geneos 434,387 0  
Net unrealized loss on available-for-sale equity securities 847,958 5,050,092  
Non-cash lease expense 278,290 0  
Unrealized transaction loss on foreign-currency denominated debt (176,927) (681,151)  
Changes in operating assets and liabilities:      
Accounts receivable 8,648,045 58,430  
Accounts receivable from affiliated entities 156,808 697,846  
Prepaid expenses and other current assets (19,214,780) (894,606)  
Prepaid expenses and other current assets from affiliated entities 106,432 (740,469)  
Other assets 75,514 191,937  
Accounts payable and accrued expenses 4,735,352 (7,217,676)  
Accrued clinical trial expenses (2,579,476) 1,011,439  
Accounts payable and accrued expenses due to affiliated entities 125,292 (466,273)  
Deferred revenue (34,963) (26,297)  
Deferred revenue from affiliated entities (37,500) (31,250)  
Operating lease right-of-use assets and liabilities, net (558,140) (517,949)  
Grant funding liability (2,461,326) 7,026,212  
Grant funding liability from affiliated entities (19,500) (49,250)  
Other liabilities 6,478 36,501  
Net cash used in operating activities (52,867,428) (25,452,721)  
Cash flows from investing activities:      
Purchases of investments (275,408,976) (56,698,250)  
Proceeds from sale or maturity of investments 504,464 5,030,257  
Purchases of capital assets (210,824) (140,952)  
Net cash used in investing activities (275,115,336) (51,808,945)  
Cash flows from financing activities:      
Proceeds from issuance of common stock, net of issuance costs 162,105,030 208,241,933  
Proceeds from stock option exercises 2,632,996 5,173,534  
Taxes paid related to net share settlement of equity awards (3,834,785) (2,072,831)  
Acquisition of non-controlling interest 0 2,169,998  
Net cash provided by financing activities 160,903,241 213,512,634  
Effect of exchange rate changes on cash and cash equivalents (14,419) 0  
Increase (Decrease) in cash and cash equivalents (167,093,942) 136,250,968  
Cash and cash equivalents, beginning of period 250,728,118 22,196,097 $ 22,196,097
Cash and cash equivalents, end of period 83,634,176 158,447,065 $ 250,728,118
Supplemental disclosures:      
Amounts accrued for purchases of property and equipment 35,370 0  
Interest paid 544,315 2,590,196  
Amortization Of Operating Lease Right-Of-Use Assets $ 0 $ 271,628